Praxis Precision Medicines Inc.
Mitchell Dean J Files Praxis Precision Medicines (PRAX) Form 4 - September 24, 2025
Transactions
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| MITCHELL DEAN J | 2025-09-24 | Buy | 1.8K | $44.04 | $77.2K | Direct |
| MITCHELL DEAN J | 2025-09-24 | Buy | 8.6K | $44.25 | $379.0K | Direct |
| MITCHELL DEAN J | 2025-09-24 | Buy | 1.9K | $14.36 | $27.7K | Direct |
| MITCHELL DEAN J | 2025-09-24 | Sell | 1.9K | $0.00 | $0.00 | Direct |
| MITCHELL DEAN J | 2025-09-24 | Sell | 1.8K | $0.00 | $0.00 | Direct |
| MITCHELL DEAN J | 2025-09-24 | Sell | 8.6K | $0.00 | $0.00 | Direct |
Profitelligence Alerts
Track PRAX insider activity
Get alerts when Praxis Precision Medicines Inc. executives trade their shares.
Advertisement
About Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.
Official SEC Documents
Advertisement